Buys | $0 | 0 | 0 |
Sells | $96,483,616 | 29 | 100 |
Tulipano Stephen J | CFO | 0 | $0 | 1 | $25,102 | $-25,102 |
Allan Jonathan | GENERAL COUNSEL & CORP SEC | 0 | $0 | 5 | $521,189 | $-521,189 |
Kaye Edward M. MD | CEO | 0 | $0 | 4 | $888,524 | $-888,524 |
Ticho Barry | CHIEF MEDICAL OFFICER | 0 | $0 | 12 | $1.43M | $-1.43M |
Nash Huw M. | COO & CBO | 0 | $0 | 4 | $1.64M | $-1.64M |
Skorpios Trust | 10 percent owner | 0 | $0 | 3 | $91.98M | $-91.98M |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the …
Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $96.48M worth of Stoke Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $29.25M and sold $23.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.
2024-12-23 | Sale | Skorpios Trust | 10 percent owner | 2M 3.6956% | $11.50 | $23M | -15.59% | |
2024-12-09 | Sale | Kaye Edward M. MD | CEO | 6,786 0.0122% | $12.99 | $88,158 | -25.00% | |
2024-12-09 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 2,586 0.0046% | $12.99 | $33,596 | -25.00% | |
2024-12-09 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 13,666 0.0256% | $13.61 | $185,978 | -25.00% | |
2024-12-06 | Sale | Kaye Edward M. MD | CEO | 6,170 0.0113% | $12.78 | $78,837 | -21.51% | |
2024-12-06 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 13,945 0.0256% | $12.78 | $178,182 | -21.51% | |
2024-12-06 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 9,696 0.0178% | $12.78 | $123,891 | -21.51% | |
2024-12-02 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.07 | $120,698 | -12.51% | |
2024-11-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.68 | $126,803 | -13.80% | |
2024-10-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0187% | $12.06 | $120,648 | -7.60% | |
2024-09-19 | Sale | Skorpios Trust | 10 percent owner | 1.94M 3.4152% | $14.05 | $27.22M | -23.32% | |
2024-09-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $14.95 | $149,481 | -21.42% | |
2024-08-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.019% | $14.58 | $145,843 | -17.80% | |
2024-07-02 | Sale | Nash Huw M. | Chief Business Officer | 2,500 0.0049% | $13.11 | $32,779 | -3.62% | |
2024-07-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0204% | $13.75 | $137,458 | -10.81% | |
2024-06-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $15.22 | $152,185 | -17.83% | |
2024-05-20 | Sale | Kaye Edward M. MD | CEO | 42,350 0.0779% | $15.43 | $653,529 | -20.31% | |
2024-05-20 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 8,599 0.0154% | $15.04 | $129,327 | -20.31% | |
2024-05-20 | Sale | Nash Huw M. | COO & CBO | 50,000 0.0917% | $15.39 | $769,500 | -20.31% | |
2024-05-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $11.37 | $113,653 | +10.55% |
Harrison Seth Loring | 17161713 32.4008% | $154.46M | 2 | 0 | <0.0001% | |
Apple Tree Partners IV, L.P. | 10 percent owner | 17161713 32.4008% | $154.46M | 2 | 0 | <0.0001% |
RTW INVESTMENTS, LP | 10 percent owner | 3544248 6.6914% | $31.9M | 6 | 1 | <0.0001% |
$587,109,125 | 90 | 3.17% | $521.31M | |
$14,527,743 | 76 | 38.40% | $482.25M | |
$24,384,691 | 42 | -30.27% | $459.77M | |
$6,280,187 | 19 | 6.80% | $493.08M | |
$100,566,697 | 18 | -5.10% | $455.67M |
Increased Positions | 68 | +49.64% | 9M | +14.99% |
Decreased Positions | 58 | -42.34% | 6M | -9.92% |
New Positions | 29 | New | 7M | New |
Sold Out Positions | 17 | Sold Out | 257,411 | Sold Out |
Total Postitions | 147 | +7.3% | 61M | +5.07% |
Skorpios Trust | $59,393.00 | 13.03% | 6.91M | -2M | -22.46% | 2024-12-31 |
Blackrock, Inc. | $50,633.00 | 11.11% | 5.89M | +317,361 | +5.7% | 2024-12-31 |
Lynx1 Capital Management Lp | $44,610.00 | 9.79% | 5.19M | 0 | 0% | 2024-12-31 |
Rtw Investments, Lp | $44,062.00 | 9.67% | 5.12M | +471,240 | +10.13% | 2024-12-31 |
Baker Bros. Advisors Lp | $39,851.00 | 8.74% | 4.63M | +265,395 | +6.08% | 2024-12-31 |
Redmile Group, Llc | $39,505.00 | 8.67% | 4.59M | -119,880 | -2.54% | 2024-12-31 |
Morgan Stanley | $29,560.00 | 6.49% | 3.44M | -768,063 | -18.26% | 2024-12-31 |
Cowen And Company, Llc | $27,903.00 | 6.12% | 3.24M | -121,246 | -3.6% | 2024-09-30 |
Toronto Dominion Bank | $27,290.00 | 5.99% | 3.17M | +3M | New | 2024-12-31 |
Vanguard Group Inc | $23,488.00 | 5.15% | 2.73M | -28,049 | -1.02% | 2024-12-31 |